Tag Archives: College of Medicine

bioscience

TGen's Zenhausern is named an NAI fellow

Dr. Frederic Zenhausern, a Professor at the Translational Genomics Research Institute (TGen) and developer of a rapid DNA processor, has been named to the Fellows of the National Academy of Inventors (NAI).

Zenhausern, Ph.D., MBA, will be inducted into the NAI Fellows by Deputy U.S. Commissioner for Patents Andy Faile, from the U.S. Patent and Trademark Office, during the 3rd Annual Conference of the National Academy of Inventors, March 7, 2014, in Alexandria, Va.  Fellows will be presented with a special trophy and a rosette pin.

Zenhausern also is a Professor and Director of the Center for Applied Nanobioscience and Medicine at the University of Arizona College of Medicine – Phoenix. The center uniquely applies a combination of advances in nanoscience, microelectromechanical systems, molecular biology, and genomics to a new generation of biological tools and sensors based on nano and microscale technologies.

Applying interdisciplinary science approaches to medicine, Zenhausern’s work is aimed at early diagnostics of human diseases, in particular, integrating bioassay chemistries with several biomarkers and targets developed by researchers at TGen.. Over the years, his team has collaborated on multiple projects at TGen for designing bioanalytical  platform technologies to translate molecular analysis into clinical tools and, ultimately, promoting adoption of novel technologies for point-of-care diagnostics applications.

The Microfluidic DNA Analysis System (MiDAS), a desktop printer-sized box that is described as robust and user-friendly, is one of Zenhausern’s innovations. The integrated DNA analyzer can be transported directly to a point-of-care or deployed in a mobile setting, eliminating some of the issues that arise when collecting and shipping a specimen from a remote site to a centralized laboratory for molecular testing. The core technology is also enabling the rapid automation of preparation of a biological sample for interfacing with various high-resolution analytical instrumentations, such as Next Generation Sequencing. These emerging diagnostic tools in personalized medicine are being used the team of clinicians at TGen Clinical Translational Research Division.

A similar platform was configured for genomic assays ready for implementations in medical countermeasures against radiological and nuclear disasters, and also applicable in clinical settings for predicting which patients are most sensitive to radiation in guiding personalized treatment, and preventing the development of toxicities that may result from radiotherapy. These innovations are described in multiple patents with TGen co-inventors, which led to significant federal funding of Arizona academic institutions, and to generating commercial interest and licensing from multiple U.S. companies, also contributing to Arizona’s economic development.

Zenhausern has co-authored more than 70 scientific publications and is named on many pending and more than a dozen issued U.S. patents in various domains ranging from DNA sequencing to optical data storage. Zenhausern’s responsibilities also include leading clinical research at the personalized medicine research laboratory at Scottsdale Healthcare Research Institute and serving on several corporate scientific boards and international consortia in life sciences.

Election to NAI Fellow status is a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.

The 143 innovators elected to NAI Fellow status represent 94 universities and governmental and non-profit research institutes.  Together, they hold more than 5,600 U.S. patents.

Included in the 2013 class are 26 presidents and senior leadership of research universities and non-profit research institutes, 69 members of the National Academies, five inductees of the National Inventors Hall of Fame, six recipients of the U.S. National Medal of Technology and Innovation, and nine Nobel Laureates among other major awards and distinctions.

Academic inventors and innovators elected to the rank of NAI Fellow were nominated by their peers for outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation.

bioscience

TGen’s Zenhausern is named an NAI fellow

Dr. Frederic Zenhausern, a Professor at the Translational Genomics Research Institute (TGen) and developer of a rapid DNA processor, has been named to the Fellows of the National Academy of Inventors (NAI).

Zenhausern, Ph.D., MBA, will be inducted into the NAI Fellows by Deputy U.S. Commissioner for Patents Andy Faile, from the U.S. Patent and Trademark Office, during the 3rd Annual Conference of the National Academy of Inventors, March 7, 2014, in Alexandria, Va.  Fellows will be presented with a special trophy and a rosette pin.

Zenhausern also is a Professor and Director of the Center for Applied Nanobioscience and Medicine at the University of Arizona College of Medicine – Phoenix. The center uniquely applies a combination of advances in nanoscience, microelectromechanical systems, molecular biology, and genomics to a new generation of biological tools and sensors based on nano and microscale technologies.

Applying interdisciplinary science approaches to medicine, Zenhausern’s work is aimed at early diagnostics of human diseases, in particular, integrating bioassay chemistries with several biomarkers and targets developed by researchers at TGen.. Over the years, his team has collaborated on multiple projects at TGen for designing bioanalytical  platform technologies to translate molecular analysis into clinical tools and, ultimately, promoting adoption of novel technologies for point-of-care diagnostics applications.

The Microfluidic DNA Analysis System (MiDAS), a desktop printer-sized box that is described as robust and user-friendly, is one of Zenhausern’s innovations. The integrated DNA analyzer can be transported directly to a point-of-care or deployed in a mobile setting, eliminating some of the issues that arise when collecting and shipping a specimen from a remote site to a centralized laboratory for molecular testing. The core technology is also enabling the rapid automation of preparation of a biological sample for interfacing with various high-resolution analytical instrumentations, such as Next Generation Sequencing. These emerging diagnostic tools in personalized medicine are being used the team of clinicians at TGen Clinical Translational Research Division.

A similar platform was configured for genomic assays ready for implementations in medical countermeasures against radiological and nuclear disasters, and also applicable in clinical settings for predicting which patients are most sensitive to radiation in guiding personalized treatment, and preventing the development of toxicities that may result from radiotherapy. These innovations are described in multiple patents with TGen co-inventors, which led to significant federal funding of Arizona academic institutions, and to generating commercial interest and licensing from multiple U.S. companies, also contributing to Arizona’s economic development.

Zenhausern has co-authored more than 70 scientific publications and is named on many pending and more than a dozen issued U.S. patents in various domains ranging from DNA sequencing to optical data storage. Zenhausern’s responsibilities also include leading clinical research at the personalized medicine research laboratory at Scottsdale Healthcare Research Institute and serving on several corporate scientific boards and international consortia in life sciences.

Election to NAI Fellow status is a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.

The 143 innovators elected to NAI Fellow status represent 94 universities and governmental and non-profit research institutes.  Together, they hold more than 5,600 U.S. patents.

Included in the 2013 class are 26 presidents and senior leadership of research universities and non-profit research institutes, 69 members of the National Academies, five inductees of the National Inventors Hall of Fame, six recipients of the U.S. National Medal of Technology and Innovation, and nine Nobel Laureates among other major awards and distinctions.

Academic inventors and innovators elected to the rank of NAI Fellow were nominated by their peers for outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation.

Z-SSH-M-0020

UA, SynDaver Announce Collaboration

Medical education at the University of Arizona College of Medicine – Phoenix has received a big boost with the latest in simulation technology from SynDaver™ Labs – and the city will get an economic boost as well.

Phoenix Mayor Greg Stanton, UA College of Medicine – Phoenix Dean Stuart D. Flynn, MD, and SynDaver™ Labs’ President Christopher Sakezles, PhD, on Wednesday, announced an exclusive collaboration between the medical school and Tampa, Fla.,-based SynDaver™ Labs. Sakezles said it could create up to 1,000 jobs over the next several years.

“We are bringing SynDaver to the forefront of medical education,” said Teresa Wu, MD, an emergency room physician at Maricopa Medical Center and faculty member of the college. “We are developing a team of practitioners that is going to help enhance medical education and improve patient safety.”

The announcement was during in an exclusive demonstration event at the Arizona Center for Simulation and Experiential Learning, on the fourth floor of the Health Sciences Education Building on campus.

“This collaboration places our college on a trajectory as a national leader among elite medical schools in simulation technology,” Dr. Flynn said. “We are ensuring medical education is not just on the cutting edge, but visionary in preparing our students to serve for the decades to come.”

Developed by SynDaver Labs, the teaching tools helps in anatomy and physiology instruction for medical and other health-related education. The company manufactures the world’s most sophisticated synthetic human tissues and body parts.

“This is all about medical education and reducing the cost of health care in general,” said Sakezles, the founder of SynDaver™ Labs. “Simulation is one of the ways we are going to do that. This particular technology is transformational. It’s been in the works for about two decades now.”

The technology is used to replace live animals, cadavers, and human patients in clinical training and surgical simulation.

“SynDaver models are unique and they are one of the best in the country, they were actually developed to allow medical students the opportunity to practice procedures and to develop skills they normally would have to do on patients in the past,” Dr. Wu said. “But now they have these task trainers that are realistic and life-like that they can practice their procedures on prior to doing it on a live patient.”

The simulation center is a new, state-of-the-art endeavor that combines technology with healthcare-focused education. Students get to learn the difficulties faced every day in the medical world, no matter how much experience they have. The simulation lab can be set up to encompass a wide variety of situations, training the students for the world they will soon enter in real patient care.